医药上市公司2025年三季度业绩回顾:结构分化 创新药产业链表现出色

中信建投证券
Nov 05

核心观点:医药上市公司已完成2025年三季度业绩披露。整体看,2025年前三季度,医药行业整体营收及扣非净利润分别同比下滑1.98%和11.60%,仍然承压,但降幅较上半年有所收窄。分子行业看,生物制药上游、医疗信息化、CRO/CMO、科研试剂等板块的扣非净利润增速排序靠前;生物制药上游、CRO/CMO、医疗设备和家用器械板块呈现收入和扣非归母净利润的双重增长。全板块营收及扣非净利润仍同比下滑,但...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10